Clarametyx Biosciences (a clinical-stage company developing targeted and immune-enabling biologic therapies to counter persistent infections associated with biofilms) and Kineticos Life Sciences (a life sciences investor focused on companies looking to disrupt how drugs are developed, diseases are diagnosed, and patients are treated) announced an investment by the Kineticos AMR Accelerator Fund I. Aligned with the funding, KAMRA Venture Partner Douglas Thomson will join the Clarametyx Board of Directors.
This funding extends the company’s Series A funding completed in 2024 to drive momentum across the Clarametyx pipeline, including the ongoing CMTX-101 trial in cystic fibrosis-related infections in collaboration with the Cystic Fibrosis Foundation and the development of the CMTX-301 vaccine against recurrent bacterial infections, which CARB-X recently funded.
KEY QUOTES:
“We graciously welcome the KAMRA Fund as an investor and advisor to Clarametyx. As a dedicated champion for innovation and operational excellence, the KAMRA team brings a like-minded sense of urgency and purpose to our mission, and we are confident they will propel our efforts as we work to address critical unmet needs in chronic respiratory disease.”
- David Richards, Chief Executive Officer, Clarametyx
“The Clarametyx scientific strategy is well aligned to our core focus on technologies and solutions to address antimicrobial resistance. We are eager to partner with the Clarametyx team to accelerate development and bring forward a potentially transformative platform strategy for this urgent global challenge.”
- Douglas Thomson, Venture Partner at the KAMRA Fund
